Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
York Space Systems Q1 2026 Earnings Call - Backlog Surges 18% Amid Strategic M&A and Supply Chain Investments
York Space Systems delivered a $116.3 million top line in Q1 2026, marking a 9% year-over-year increase and underscoring the early momentum following its January IPO. The company is aggressively pivot...
- Revenue reached $116.3 million in Q1 2026, up 9% year-over-year and ahead of management expectations, driven by growth in major government programs.
- Backlog increased 18% to $642.3 million, fueled by a new $187 million commercial contract for a 20-plus satellite constellation and multiple new government IDIQ awards.
- Gross margin contracted to 19%, down 400 basis points year-over-year, primarily due to non-recurring EAC adjustments and accelerated depreciation charges.
- +11 more takeaways
Data I/O Corporation Q1 2026 Earnings Call - Transformational Acquisition to Double Revenue Amid Pivot to Services
Data I/O reported a challenging Q1 2026 with net sales falling to $3.3 million, down from $6.2 million in the prior year quarter, driven by a slower-than-expected ramp in new sales initiatives and bro...
- Q1 2026 net sales fell 47% year-over-year to $3.3 million, reflecting a slower ramp in new sales initiatives and lower bookings carrying over from Q4 2025.
- Q1 bookings accelerated to $4.2 million, up from $3.1 million in Q4 2025, with strong late-quarter momentum in Europe and North America.
- CEO Bill Wentworth provided first-ever revenue guidance, projecting Q2 2026 revenue between $5.0 million and $5.4 million, implying at least 20% sequential growth.
- +12 more takeaways
Omeros Corporation Q1 2026 Earnings Call - YARTEMLEA Launch Outpaces Expectations, Cash Flow Positive
Omeros Corporation’s Q1 2026 results were defined by the rapid commercial rollout of YARTEMLEA, its first approved MASP-2 inhibitor for TA-TMA. The drug generated $9.9 million in net revenue within we...
- YARTEMLEA generated $9.9 million in net revenue in Q1 2026, just weeks after launch, driven by strong early adoption across transplant centers.
- Company achieved cash flow positivity in Q1 2026 despite mid-January launch, with expectations of sustained positive cash flow within 18 months.
- 30 unique accounts ordered YARTEMLEA by March 31, with 60% of top 10 centers and 30% of top 80 centers receiving P&T approvals ahead of typical timelines.
- +7 more takeaways
BioStem Q1 2026 Earnings Call - Hospital Pivot Drives $25M-$29M 2026 Guidance Amid Margin Expansion Roadmap
BioStem completed a transformative acquisition in late January 2026, shifting its strategic focus from a physician office-centric model to a hospital-focused commercial infrastructure. The deal added ...
- Strategic Pivot to Hospital Channel: BioStem completed a transformative acquisition in late January 2026, repositioning the company from a physician office-focused model to a hospital-centric commercial infrastructure with access to major GPO contracts and a diversified perinatal tissue allograft portfolio.
- Seamless Integration and Revenue Stability: Hospital revenue reached $5.4 million in Q1 2026, matching the pro-forma performance of the acquired Neox and Clarix assets over a comparable 70-day period, demonstrating minimal disruption during the transition.
- Sales Force Expansion: The direct sales team nearly doubled to 35 representatives, with plans to reach 40 by year-end, supported by over 30 independent sales agents to drive deeper penetration across key hospital call points.
- +7 more takeaways
CXAI Q1 2026 Earnings Call - Agentic AI Wins Drive $5M TCV Despite Revenue Dip
CXAI reported a slight decline in Q1 2026 revenue to $950,000, driven by the timing of enterprise deal closures and revenue recognition patterns. However, the company secured $1.4 million in bookings,...
- Revenue declined 6.9% quarter-over-quarter to $950,000, reflecting timing delays in revenue recognition rather than demand weakness.
- Bookings surged 12.5% year-over-year to $1.4 million, including three new three-year enterprise deals worth $5 million in total contract value.
- Net revenue retention jumped to 98%, up 12 percentage points year-over-year, signaling strong customer expansion and product stickiness.
- +7 more takeaways
Infleqtion Q1 2026 Earnings Call - Momentum Drives Revenue Beat and Expanded Quantum Platform
Infleqtion delivered a strong start to 2026, posting a record first-quarter revenue of $9.5 million, a 14% year-over-year increase driven entirely by quantum solutions. Management raised its full-year...
- Record Q1 revenue of $9.5 million, up 14% year-over-year, driven entirely by quantum solutions.
- Full-year 2026 revenue guidance raised to at least $40 million, signaling accelerated growth.
- Company maintains a single neutral atom platform strategy across computing, sensing, and timing products.
- +7 more takeaways
Insight Molecular Diagnostics Q1 2026 Earnings Call - GraftAssureDx FDA Review Progress and Cash Burn Peak
Insight Molecular Diagnostics is advancing GraftAssureDx through the FDA review process with no clock stops, while building early international revenue through research-use-only sales in Europe and As...
- GraftAssureDx is under FDA review with no clock stops, and management expects the first U.S. orders later this year.
- Early international sales are already underway, with a Swiss transplant hospital purchasing kits and Southeast Asian orders expected.
- The GALACTIC Registry Study has expanded to 34 U.S. centers, up from 28, with the first clinical trial agreement signed.
- +7 more takeaways
Energous Wireless Power Solutions Q1 2026 Earnings Call - Fortune 10 Deployments Drive 10x Revenue Surge
Energous Wireless Power Solutions reported a stark acceleration in its commercialization trajectory, with Q1 2026 revenue jumping tenfold to $3.1 million. The company has moved decisively past the pro...
- Q1 2026 revenue surged to $3.1 million, a tenfold increase from $0.3 million in the prior year period, marking the fifth consecutive quarter of revenue growth.
- Two active Fortune 10 commercial deployments are driving the acceleration, including a major retailer with over 1,500 U.S. locations and an e-commerce fulfillment company expanding internationally.
- The company has deployed more than 39,000 PowerBridge transmitters, with the flagship PowerBridge PRO achieving zero returns since commercial production began in 2024.
- +7 more takeaways
Electrovaya Inc. Q2 2026 Earnings Call - Energy Storage and Robotics Deliveries Accelerate Amid Supply Chain Headwinds
Electrovaya reported strong Q2 2026 results with revenue up 20% to $18 million and net profit surging 404% to $1 million year-over-year. The company is strategically pivoting beyond its traditional ma...
- Q2 2026 revenue reached $18 million, a 20% year-over-year increase, with six-month revenue up 28% to $33.6 million.
- Net profit surged 404% to $1 million in Q2, marking the fifth consecutive quarter of profitability and positive EPS.
- Gross margin expanded 230 basis points to 33.4%, driven by favorable product mix and disciplined cost management.
- +7 more takeaways
Blaize Holdings Inc Q1 2026 Earnings Call - Recurring AI Services Pivot and Supply Chain Shift
Blaize Holdings reported a modest $2.7 million in Q1 2026 revenue, a 170% year-over-year increase, though the figure was heavily constrained by an industry-wide High Bandwidth Memory shortage that del...
- Q1 2026 revenue came in at $2.7 million, up 170% year-over-year, but remained constrained by an industry-wide High Bandwidth Memory shortage that delayed a major order.
- The company reaffirmed its full-year 2026 revenue guidance of $130 million, with management explicitly stating that revenue will be heavily back-half weighted.
- Gross margins expanded significantly to 58% in Q1, up from 11% in Q4 2025, driven by a shift toward higher-margin software and partner-branded hardware.
- +7 more takeaways